Company: CDT
Filing Date: 2025-01-23
Form Type: 8-K
Source: 0001493152-25-003316
Chunk: 0

Company: CDT Equity Inc.
Filing Date: 2025-01-23
Form: 8-K
Item: Item 3.03
Chunk 0
---
Item
3.03 Material Modification to Rights of Security Holders.

To
the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K (the “ Current
Report”) is incorporated herein by reference.

Item
5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On
January 22, 2025, Conduit Pharmaceuticals Inc. (the “ Company”) filed a certificate of amendment to the Company’s Second
Amended and Restated Certificate of Incorporation (the “ Amendment”) with the Secretary of State of the State of Delaware
to effectuate a 1-for-100 reverse stock split (the “ Reverse Stock Split”) of the outstanding shares of the Company’s
common stock (“ Common Stock”). The Company’s stockholders previously approved the Reverse Stock Split and granted the
board of directors the authority to determine the exact split ratio and when to proceed with the Reverse Stock Split at the Company’s
annual meeting of stockholders held on December 18, 2024.

The
Reverse Stock Split will become effective on January 24, 2025 at 5:00 p. m., Eastern Time (the “ Effective Time”) and the Common
Stock is expected to begin trading on The Nasdaq Global Market on a Reverse Stock Split-adjusted basis on January 27, 2025 at market
open under the existing ticker symbol, “ CDT.” As of the Effective Time, every 100 shares of the Company’s issued and
outstanding Common Stock will be combined into one share of Common Stock.

The
par value and other terms of the Common Stock will not be affected by the Reverse Stock Split. The Company’s post-Reverse Stock
Split Common Stock CUSIP number will be 20678X 205.

No
fractional shares will be issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive
a fractional share of Common Stock will receive a cash payment in lieu thereof at a price equal to the fraction to which the stockholder
would otherwise be entitled multiplied by the closing price per share of the Common Stock (as adjusted for the Reverse Stock Split) on
the Nasdaq Global Market on January 24, 2025.

The
foregoing description of the Amendment is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit
3.1 to this